Engraftment of primary T-ALL cells in secondary NOD/SCID recipients with or without cord blood preconditioning.
Representative results are presented for a mouse preconditioned with cord blood (A, B) and for a mouse that received no cord blood (C, D). One group of mice was injected with 25 × 106 human cord blood MNCs 8 days before injection with 2.4 × 106T-ALL cells from engrafted spleen. A second group of mice received no cord blood MNCs before injection of T-ALL cells. Human T-ALL constituted 92% of the injected engrafted mouse spleen cells on the basis of CD5 and CD7 expression (not shown). Mice in the first group were killed 5 weeks after T-ALL injection, whereas mice in the second group were killed 6 weeks after T-ALL injection. Bone marrow (A, C) and spleen (B, D) cells were analyzed by flow cytometry for several T-ALL markers, as described in “Materials and methods.” Percentages of human CD5+ and CD7+ cells were determined using CellQuest 3.2.1 software and are indicated in the panels.
